Antineoplastic effects of 1,25(OH)2D3 and its analogs in breast, prostate and colorectal cancer

Abstract

The active form of vitamin D3, 1,25-dihydroxyvitamin D3(1,25(OH)2D3), is mostly known for its importance in the maintenance of calcium and phosphate homeostasis. However, next to its classical effects on bone, kidney and intestine, 1,25(OH)2D3also exerts antineoplastic effects on various types of cancer. The use of 1,25(OH)2D3itself as treatment against neoplasia is hampered by its calcemic side effects. Therefore, 1,25(OH)2D3-derived analogs were developed that are characterized by lower calcemic side effects and stronger antineoplastic effects. This review mainly focuses on the role of 1,25(OH)2D3in breast, prostate and colorectal cancer (CRC) and the underlying signaling pathways. 1,25(OH)2D3and its analogs inhibit proliferation, angiogenesis, migration/invasion and induce differentiation and apoptosis in malignant cell lines. Moreover, prostaglandin synthesis and Wnt/b-catenin signaling are also influenced by 1,25(OH)2D3and its analogs. Human studies indicate an inverse association between serum 25(OH)D3values and the incidence of certain cancer types. Given the literature, it appears that the epidemiological link between vitamin D3and cancer is the strongest for CRC, however more intervention studies and randomized placebo-controlled trials are needed to unravel the beneficial dose of 1,25(OH)2D3and its analogs to induce antineoplastic effects.